(HLF) Herbalife Nutrition - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: KYG4412G1010
HLF: Weight Management, Targeted Nutrition, Energy, Sports, Outer Nutrition
Herbalife Ltd., a global leader in the health and wellness industry, operates in over 90 countries, offering a diverse range of nutrition and personal care products. The companys product portfolio includes weight management solutions such as meal replacements, protein shakes, and metabolism boosters; targeted nutrition products like herbal supplements and vitamins; energy and sports performance products; and outer nutrition offerings like skin, body, and hair care. Herbalife also provides educational materials and sales tools to its distributors. The companys distribution network includes independent service providers, sales representatives, and company-operated retail platforms. Formerly known as Herbalife Nutrition Ltd., the company rebranded as Herbalife Ltd. in April 2023. Founded in 1980, Herbalife is headquartered in Los Angeles, California, and has established itself as a key player in the direct sales industry, focusing on nutrition and wellness.
From a technical perspective, Herbalifes stock (NYSE:HLF) is currently trading at $6.86, with a 20-day moving average of $6.82. The stock is below its 50-day ($7.76) and 200-day ($7.64) moving averages, indicating bearish momentum. The average true range (ATR) of $0.50 suggests moderate volatility. On the fundamental side, the company has a market capitalization of $729.66 million, with a price-to-earnings (P/E) ratio of 2.88 and a forward P/E of 3.43. The price-to-sales (P/S) ratio of 0.14 reflects a low valuation relative to its revenue. However, the return on equity (RoE) of -31.79% raises concerns about profitability. Considering these factors, the stock may face near-term pressure due to its negative earnings growth and declining moving averages. Long-term investors may look for signs of operational turnaround and improved profitability to justify re-entry into the stock.
Additional Sources for HLF Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HLF Stock Overview
Market Cap in USD | 730m |
Sector | Consumer Defensive |
Industry | Packaged Foods |
GiC Sub-Industry | Personal Care Products |
IPO / Inception | 2004-12-16 |
HLF Stock Ratings
Growth Rating | -85.4 |
Fundamental | -7.22 |
Dividend Rating | 8.61 |
Rel. Strength | -38.7 |
Analysts | 3.25/5 |
Fair Price Momentum | 4.76 USD |
Fair Price DCF | 34.80 USD |
HLF Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 34.4% |
HLF Growth Ratios
Growth Correlation 3m | -13.3% |
Growth Correlation 12m | -64% |
Growth Correlation 5y | -95.3% |
CAGR 5y | -29.30% |
CAGR/Max DD 5y | -0.32 |
Sharpe Ratio 12m | -0.59 |
Alpha | -36.66 |
Beta | 0.040 |
Volatility | 62.31% |
Current Volume | 1984.2k |
Average Volume 20d | 2105.2k |
As of May 09, 2025, the stock is trading at USD 6.99 with a total of 1,984,215 shares traded.
Over the past week, the price has changed by +5.43%, over one month by -0.99%, over three months by +33.40% and over the past year by -32.20%.
Neither. Based on ValueRay Fundamental Analyses, Herbalife Nutrition is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HLF as of May 2025 is 4.76. This means that HLF is currently overvalued and has a potential downside of -31.9%.
Herbalife Nutrition has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold HLF.
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, HLF Herbalife Nutrition will be worth about 5.2 in May 2026. The stock is currently trading at 6.99. This means that the stock has a potential downside of -26.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.3 | 33.5% |
Analysts Target Price | 9.3 | 33.5% |
ValueRay Target Price | 5.2 | -26.3% |